Clinical Trial Update: Copanlisib Plus Venetoclax in R/R DLBCL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study conducted by the Dana-Farber Cancer Institute is evaluating the combination of copanlisib and venetoclax in relapsed or refractory diffu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING